Skip to main content
TipRanks
Go Ultimate75% OFF

Neogen (NEOG) AI Stock Analysis

287 Followers
NEOG

Neogen

(NASDAQ:NEOG)

Select Model
Rating:60Neutral
Price Target:$12.50▲(14.68% Upside)
Action:reiterated
Date:10/07/26

NEOG’s score is driven primarily by improving fundamentals signaled in the latest earnings call (raised FY27 guidance and expectations for meaningful cash flow improvement) and a relatively supportive financial base (stronger balance sheet and recent positive free cash flow). These positives are tempered by ongoing net losses and historical earnings volatility, while technical indicators and valuation (negative P/E and no dividend yield provided) remain moderate-to-weak.

Positive Factors
Recurring consumables modelNeogen benefits from repeat testing tied to regulatory standards and customer quality programs. Consumable replenishment can create recurring revenue, while instruments and workflow products support cross-selling and deepen customer relationships over time.
Negative Factors
Persistent unprofitabilityOngoing net losses and negative EBIT show that revenue has not yet translated into consistent GAAP profitability. This weakens earnings quality, limits internally generated capital, and leaves results more exposed to execution issues or cost increases over the medium term.

Neogen Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$50.00M$100.00M$150.00M$200.00M$250.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

There’s a clear step-up in the business around late‑2022 that lifted the revenue baseline in both Domestic and International—consistent with portfolio expansion rather than a one‑quarter spike—and since then the two regions have traded places as the primary growth driver. Post‑2022 results look range‑bound and seasonal, so future upside will likely come from execution (pricing, new products, M&A) and stronger international penetration; watch integration, international margin trends, and whether overseas growth sustains beyond occasional quarter-to-quarter beats.

Data provided by:The Fly

Neogen (NEOG) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%NEOG+90.56%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.38B
Dividend Yield
―
Average Volume (3M)
3.47M
Price to Earnings (P/E)
-43.1
Beta (1Y)
0.84
Revenue Growth
-0.33%
EPS Growth
94.64%
Country
US
Employees
2,636
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Neogen Business Overview & Revenue Model

Company Description

Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary div...

How the Company Makes Money

Neogen primarily makes money by selling products and services that support testing and monitoring in food safety and animal safety workflows. A major portion of revenue is generated from recurring consumables and test kits used in routine screening (...

Neogen Earnings Call Summary

Earnings Call Date:Oct 06, 2026(Q1-2027)|% Change Since:-8.86%|Next Earnings Date:Jan 14, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Neogen reported broad-based revenue growth, improved adjusted EBITDA margins and free cash flow, raised fiscal 2027 guidance, advanced commercial and innovation initiatives, and reached an important Petrifilm validation milestone. Management also highlighted near-term growth timing effects, macroeconomic pressures, transition-related duplicative costs and a full-year EBITDA margin outlook roughly similar to fiscal 2026, but described these issues as understood and incorporated into its plans.

Positive Updates

Revenue Growth and Encouraging Fiscal-Year Start
First-quarter revenue was $222.8 million, representing 8.1% core growth. Management described the quarter as an encouraging start to fiscal year 2027, with solid core revenue growth in both Food Safety and Animal Safety and an acceleration from the fourth quarter.

Negative Updates

First-Quarter Growth Benefited from Timing Items
The timing of certain customer orders benefited first-quarter core growth by approximately 300 basis points, with orders expected in the second quarter occurring in the first quarter instead. In addition, the prior-year first quarter was negatively affected by inventory adjustments at two large distributors.

Company Guidance

For fiscal year 2027, Neogen raised revenue guidance to $885 million to $890 million and adjusted EBITDA guidance to $181 million to $183 million, with the genomics business continuing to be included; the second quarter is expected to see the lowest level of core growth, first-half core growth is expected to be “in the range of approximately 3.5%,” and first-half adjusted EBITDA margin is expected to be “in line with the first quarter,” while full-year EBITDA margins are expected to be “roughly similar” to fiscal year '26. The company expects to expand adjusted EBITDA margins through progress in key operational efficiency programs, and maintains its view that both GAAP cash flow from operations and free cash flow will “increase meaningfully on a year-over-year basis”; the genomics divestiture is expected to receive a final decision by the end of December, with expected net proceeds of approximately $140 million, which would put net leverage below 3x at closing and closer to 2.5x by the end of the fiscal year. The Petrifilm manufacturing transfer is expected to begin the planned multi-quarter transfer next month, and after transitioning over through fiscal year '28, Neogen expects margin improvement of 200 to 300 basis points in FY '29, with improvements beginning in the first fiscal year and fully implemented in the second year.

Neogen Financial Statement Overview

Summary

Balance sheet strength is a key positive (TTM shows zero debt and a large equity base), and cash flow has recently turned positive with improved free cash flow. Offsetting that, profitability is still weak with a net loss and slightly negative EBIT, and multi-year earnings have been volatile (including a very large loss in 2025), which weighs on overall financial quality.

Income Statement

44Neutral

Balance Sheet

72Positive

Cash Flow

63Positive
Financial statement breakdown
BreakdownTTMMay 2026May 2025May 2024May 2023May 2022
Income Statement
Total Revenue883.99M870.40M894.66M924.22M822.45M527.16M
Gross Profit418.98M408.50M421.38M462.63M405.95M243.01M
EBITDA105.13M164.90M-937.75M182.60M124.39M84.34M
Net Income-56.12M-7.90M-1.09B-9.42M-22.87M48.31M
Balance Sheet
Total Assets3.30B3.35B3.44B4.55B4.55B992.93M
Cash, Cash Equivalents and Short-Term Investments172.00M185.50M129.00M170.94M245.57M381.05M
Total Debt774.20M793.70M912.61M906.24M897.53M0
Total Liabilities1.22B1.25B1.37B1.40B1.42B105.56M
Stockholders Equity2.09B2.09B2.07B3.14B3.13B887.37M
Cash Flow
Free Cash Flow49.75M31.90M-46.35M-76.16M-24.73M43.61M
Operating Cash Flow85.25M83.20M58.24M35.26M41.03M68.04M
Investing Cash Flow-35.42M70.50M-99.19M-29.31M201.04M-97.23M
Financing Cash Flow-19.01M-99.40M-1.60M1.92M-118.08M6.81M

Neogen Technical Analysis

Technical Analysis SentimentNegative
Last Price10.90

Price Trends

50DMA12.20Negative
100DMA11.48Negative
200DMA10.52Positive

Market Momentum

MACD-0.28Positive
RSI36.73Neutral
STOCH7.14Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEOG, the sentiment is Negative. The current price of 10.90 is below the 20-day moving average (MA) of 11.81, below the 50-day MA of 12.20, and above the 200-day MA of 10.52, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 36.73 is Neutral, neither overbought nor oversold. The STOCH value of 7.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEOG.

Neogen Risk Analysis

Neogen disclosed 42 risk factors in its most recent earnings report. Neogen reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We must continue to maintain an effective system of internal control over financial reporting and disclosure controls and procedures.Q2, 2026
2.We have experienced significant management transitions, and our inability to successfully integrate new leadership could adversely affect our business and strategic initiatives.Q2, 2026
3.The pending sale of our Genomics business is subject to risks and uncertainties that could affect our results.Q2, 2026

Neogen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NEOG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BIOBIO78Outperform$9.73B9.4114.07%―1.38%―
NEOGNEOG60Neutral$2.38B-43.11-2.68%―-0.33%94.64%
BRKRBRKR57Neutral$9.37B-55.94-5.15%0.33%2.16%-604.24%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RPIDRPID50Neutral$36.96M-0.67-254.31%―20.78%-9.39%
PACBPACB44Neutral$569.53M-4.39604.22%―4.41%74.75%
QTRXQTRX40Underperform$135.79M-1.21-42.99%―13.78%-1.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%NEOGBIOBRKRPACBQTRXRPIDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NEOG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NEOGNeogen10.905.49101.48%
BIOBio-Rad Laboratories358.1954.5817.98%
BRKRBruker Corporation61.3617.7140.56%
PACBPacific Biosciences1.82-0.06-3.19%
QTRXQuanterix2.86-3.05-51.61%
RPIDRapid Micro Biosystems, Inc. Class A0.74-3.32-81.87%

Neogen Corporate Events

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings

Neogen Shareholders Approve Governance, Incentive and Audit Matters

Positive
Oct 7, 2026

On October 1, 2026, Neogen Corporation held its 2026 Annual Meeting of Shareholders, with 176,180,487 of 218,106,005 eligible shares represented. Shareholders elected directors Aashima Gupta, Raphael A. Rodriguez, and Catherine E. Woteki, Ph.D., and...

Executive/Board Changes

Neogen announces board changes following director resignation

Neutral
Aug 7, 2026

Neogen Corporation, a company with a corporate governance structure that includes a Board of Directors, reported a change in its leadership at the board level. The company relies on its directors to provide strategic oversight and guidance to managem...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 07, 2026